Market Intelligence, Clinical Progress, and High-Purity Mutant Reagents for Pancreatic, Colorectal, and Non-Small Cell Lung Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KRAS G12D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Mutant) | KRAS G12D Mutant Recombinant Protein Human, Full-length, Sequence Verified. High Purity (>95%), Endotoxin <1EU/µg. |
View KRAS G12D Products |
| Antigen (WT Control) | KRAS Wild-Type Recombinant Protein High Purity (>95%), For selectivity counter-screening. |
View KRAS Products |
| Gene Delivery | KRAS G12D Premade Lentivirus Full-length ORF for stable cell line construction (Ba/F3, HEK293T). |
View KRAS G12D Products |
| Benchmark Antibody | Anti-KRAS G12D (Mutant-Specific) Recombinant Monoclonal for immunoassay development. | View KRAS G12D Products |
| Interactor Protein | SOS1 Recombinant Protein Guanine nucleotide exchange factor (GEF) for exchange kinetics assays. |
View SOS1 Products |
| Validator | KRAS siRNA Set For knockdown verification and specificity controls. |
View KRAS Products |
| Related Target A | NRAS Isoform redundancy and compensatory signaling pathway. |
View NRAS Products |
| Related Target B | SOS1 Upstream activator; direct target for indirect KRAS inhibition. |
View SOS1 Products |
Critical Assay Challenges & TarMart Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. Wild-Type Selectivity | Matched pair of G12D Mutant and WT proteins (>95% purity) with Sequence Verified identity for differential binding SPR. Also available G12C and G12V for selectivity panel. |
| GTP-Bound (Active) State Conformation | Theoretical loading with GTPγS or GppNHp analogs; suitable for effector binding assays (RAF-RBD pull-down). |
| Nucleotide Exchange Kinetics | SOS1 Recombinant Protein (HEK293 Expressed) available for coupled GEF activity assays. |
| Cellular Validation (Intracellular Target) | KRAS G12D Lentivirus for stable integration into Ba/F3 or HEK293T; Endotoxin controlled for cell health. |
| Off-Target (Pan-RAS Family) | Homolog panel available: NRAS and HRAS proteins for isoform selectivity screening. |
| Lack of Controls / False Positives | Clinical Benchmark Antibodies and validated siRNA included for assay calibration and knockdown baselines. |
Live KRAS G12D R&D Tracker
Global Clinical Landscape & Future Outlook
The race for KRAS G12D therapeutics has accelerated beyond the historic "undruggable" stigma. With first-generation G12C covalent inhibitors (Sotorasib, Adagrasib) validating the pathway, the field is now pivoting toward the more prevalent G12D mutation through non-covalent, state-specific small molecules, targeted protein degraders (PROTACs), and TCR-directed cell therapies. Because G12D lacks the reactive cysteine found in G12C, rational design has shifted to non-covalent allosteric binders and molecular glue strategies (e.g., Revolution Medicines' RMC-9805). Future development emphasizes combination strategies with checkpoint inhibitors, SOS1, SHP2, and downstream MEK/ERK pathway blockade to combat intrinsic and acquired resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Non-Covalent Small Molecule (RAS(ON) Inhibitors) | Revolution Medicines, Bristol Myers Squibb (Mirati) | Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), NSCLC | Active-State Binding & Effector Displacement (Need high-purity G12D mutant protein in GTP-loaded format) |
| Targeted Degrader (PROTAC) | Arvinas, Cullgen, Amphista | Refractory Solid Tumors | Ternary Complex Validation (Need sequence verified isoforms with correct folding) |
| TCR-T / Cell Therapy | Adaptimmune, TScan Therapeutics, Kite Pharma | PDAC, CRC, MSI-H Cancers | Mutant-Specific Antigen Validation (Need recombinant mutant protein and peptide controls) |
| mRNA / Peptide Vaccine | BioNTech, Moderna | Adjuvant setting in PDAC/CRC | Immune Monitoring & ELISPOT (Need mutant antigen for T-cell response quantification) |
| SOS1 Inhibitors | Boehringer Ingelheim | Combination therapies | Protein-Protein Interaction (SOS1-KRAS binding assays) |
Key Assay Strategies for Best-in-Class Development
- Absolute Mutant vs Wild-Type Selectivity: Use high-purity matched protein pairs (G12D vs WT) in competitive SPR/BLI to ensure >100-fold selectivity margins.
- State-Dependent Binding (ON vs OFF): Employ nucleotide-exchange assays with SOS1 and fluorescent GTP analogs to confirm compound binding preference for active (GTP-bound) vs inactive (GDP-bound) conformations.
- Intracellular Target Engagement: Build stable cell lines using KRAS G12D lentivirus for CETSA and target occupancy studies under physiological nucleotide concentrations.
- Ternary Complex Formation (for PROTACs): Validate binary and ternary complex formation via AlphaLISA or SPR using untagged or minimally tagged mutant protein (Endotoxin <1EU/µg).
- Isoform Cross-Reactivity Panel: Screen against NRAS, HRAS, and KRAS WT proteins to rule out pan-RAS liability.